AU2021248653B2 - Reducing or inhibiting ocular damage by hyaluronidase administration - Google Patents
Reducing or inhibiting ocular damage by hyaluronidase administration Download PDFInfo
- Publication number
- AU2021248653B2 AU2021248653B2 AU2021248653A AU2021248653A AU2021248653B2 AU 2021248653 B2 AU2021248653 B2 AU 2021248653B2 AU 2021248653 A AU2021248653 A AU 2021248653A AU 2021248653 A AU2021248653 A AU 2021248653A AU 2021248653 B2 AU2021248653 B2 AU 2021248653B2
- Authority
- AU
- Australia
- Prior art keywords
- minutes
- hyaluronidase
- composition
- eye
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004444P | 2020-04-02 | 2020-04-02 | |
| US63/004,444 | 2020-04-02 | ||
| PCT/US2021/025668 WO2021203062A1 (en) | 2020-04-02 | 2021-04-02 | Reducing or inhibiting ocular damage by hyaluronidase administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021248653A1 AU2021248653A1 (en) | 2022-12-01 |
| AU2021248653B2 true AU2021248653B2 (en) | 2024-05-02 |
Family
ID=77921064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021248653A Active AU2021248653B2 (en) | 2020-04-02 | 2021-04-02 | Reducing or inhibiting ocular damage by hyaluronidase administration |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11878051B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4125928A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023521059A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230005198A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115697348A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021248653B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174498A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296979A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012426A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021203062A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202211833B (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024003755A (es) * | 2021-09-25 | 2024-04-15 | Med Progress Llc | Reduccion o inhibicion del da?o tisular mediante la administracion de hialuronidasa. |
| KR102922198B1 (ko) * | 2022-04-25 | 2026-02-03 | 주식회사 메디팹 | 조직 수복용 생체재료의 분해 또는 교정용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8504025D0 (en) | 1985-02-16 | 1985-03-20 | Biopharm Ltd | Hyaluronidase |
| KR100566451B1 (ko) * | 1997-05-22 | 2006-03-31 | 이스타 파마슈티칼스, 인크. | 안질환 치료에서 초자체액의 액화를 위한 안과용 제제의 제조에 있어서의 히알루로니다제의 용도 |
| US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
| US20090311237A1 (en) * | 2008-04-14 | 2009-12-17 | Frost Gregory I | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
| US20120101033A1 (en) | 2010-10-05 | 2012-04-26 | Shantha Totada R | Retinitis pigmentosa treatment |
| US11076992B2 (en) | 2019-04-19 | 2021-08-03 | Elt Sight, Inc. | Methods of transverse placement in ELT |
-
2021
- 2021-04-02 IL IL296979A patent/IL296979A/en unknown
- 2021-04-02 JP JP2022560457A patent/JP2023521059A/ja active Pending
- 2021-04-02 WO PCT/US2021/025668 patent/WO2021203062A1/en not_active Ceased
- 2021-04-02 CN CN202180040265.2A patent/CN115697348A/zh active Pending
- 2021-04-02 AU AU2021248653A patent/AU2021248653B2/en active Active
- 2021-04-02 MX MX2022012426A patent/MX2022012426A/es unknown
- 2021-04-02 CA CA3174498A patent/CA3174498A1/en active Pending
- 2021-04-02 KR KR1020227038208A patent/KR20230005198A/ko active Pending
- 2021-04-02 EP EP21782409.3A patent/EP4125928A4/en active Pending
- 2021-04-02 US US17/221,750 patent/US11878051B2/en active Active
-
2022
- 2022-10-31 ZA ZA2022/11833A patent/ZA202211833B/en unknown
-
2026
- 2026-01-09 JP JP2026002581A patent/JP2026065067A/ja active Pending
Non-Patent Citations (6)
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202211833B (en) | 2023-04-26 |
| WO2021203062A1 (en) | 2021-10-07 |
| JP2026065067A (ja) | 2026-04-14 |
| MX2022012426A (es) | 2023-01-11 |
| CN115697348A (zh) | 2023-02-03 |
| CA3174498A1 (en) | 2021-10-07 |
| EP4125928A1 (en) | 2023-02-08 |
| US20210308234A1 (en) | 2021-10-07 |
| IL296979A (en) | 2022-12-01 |
| US11878051B2 (en) | 2024-01-23 |
| EP4125928A4 (en) | 2024-06-12 |
| JP2023521059A (ja) | 2023-05-23 |
| AU2021248653A1 (en) | 2022-12-01 |
| KR20230005198A (ko) | 2023-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tseng et al. | A randomized clinical trial of combined topical-intracameral anesthesia in cataract surgery | |
| TW539560B (en) | Ophthalmic drug delivery device | |
| JP2026065067A (ja) | ヒアルロニダーゼの投与による目の損傷の低減又は抑制 | |
| CN101107006B (zh) | 治疗黏连性关节囊炎的方法 | |
| US11890331B2 (en) | Reducing or inhibiting ocular damage by hyaluronidase administration | |
| US20240123041A1 (en) | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | |
| CRAIG BROWN et al. | Use of dilute drug solutions for routine cycloplegia and mydriasis | |
| US20250134966A1 (en) | Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration | |
| Alfayyadh et al. | Advanced eales’ disease with neovascular glaucoma at first presentation | |
| Loy et al. | Consensus on the intravitreal injection technique among infants with retinopathy of prematurity by the vitreo-retina society of the Philippines | |
| US20060034890A1 (en) | Device for ocular delivery of active principles by the transpalpebral route | |
| Murthy et al. | Is there a role for retrobulbar hyaluronidase in hyaluronic acid vascular embolism related vision loss | |
| SU1683740A1 (ru) | Способ введени лекарственных веществ дл лечени заболеваний глаз | |
| KR20100109549A (ko) | Tgf-베타 3을 사용한 흉터의 억제 | |
| Bolaji-Alabi et al. | CONSERVATIVE SURGICAL MANAGEMENT OF UNILATERAL TRAUMATIC PROPTOSIS IN AN EIGHT WEEK OLD BOERBOEL | |
| Kangastupa | A New Platform for Suprachoroidal Drug Delivery Using Standard Commercially Available Needles | |
| RU2196556C2 (ru) | Способ лечения органических и функциональных заболеваний сетчатки | |
| Andrew | Ingrowing toenails: an evaluation of two treatments | |
| Hushaw | Air Travel & IOLs | |
| Cimberle et al. | FEMCAT study evaluates value of femtosecond cataract surgery. | |
| Mittendorf | The Treatment of Detachment of the Retina | |
| Welham et al. | Squash ball to eye ball | |
| Jayson | Frozen shoulder: adhesive capsulitis | |
| Porter | Policeman's heel | |
| HK1115295B (en) | Methods for treating adhesive capsulitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |